Skip to Main Content
Directory of Faculty Research Interests
YSM Home

INFORMATION FOR

DownloadHi-Res Photo

Michael S. Leapman, MD, MHS

Associate Professor of Urology; Clinical Program Leader, Prostate & Urologic Cancers Program, Yale Cancer Center

Contact Information

Michael S. Leapman, MD, MHS

Mailing Address

  • Urology

    PO Box 208058

    New Haven, CT 06520-8058

    United States

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Dr. Leapman has been recognized for his research in urologic oncology, with an emphasis in prostate cancer, particularly in the area of risk stratification and clinical outcomes research. His work has been published widely including the Journal of Clinical Oncology, JAMA Oncology, European Urology, and the Journal of Urology. He has written numerous review articles and book chapters, and has delivered research presentations and invited lectures at regional and national meetings.

Coauthors

Research Interests

Urinary Bladder Diseases; Delivery of Health Care; Health Services Research; Kidney Diseases; Prostatic Neoplasms; Ureteral Diseases; Urologic Neoplasms

Selected Publications

  • Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation.Leapman M, Wang R, Loeb S, Seibert T, Gaylis F, Lowentritt B, Brown G, Chen R, Lin D, Witte J, Cooperberg M, Catalona W, Gross C, Ma X. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Investigative Urology 2023, 101097ju0000000000003159. PMID: 36753746, DOI: 10.1097/ju.0000000000003159.
  • Access to urologic cancer care for Medicaid-insured patientsLaditi F, Nie J, Hsiang W, Umer W, Haleem A, Marks V, Buck M, Leapman M. Access to urologic cancer care for Medicaid-insured patients Urologic Oncology Seminars And Original Investigations 2023 PMID: 36740488, DOI: 10.1016/j.urolonc.2023.01.014.
  • Prostate cancer disparities among American Indians/Alaskan Natives in the United States.Chu C, Leapman M, Zhao S, Cowan J, Washington S, Cooperberg M. Prostate cancer disparities among American Indians/Alaskan Natives in the United States. Journal Of The National Cancer Institute 2023 PMID: 36629492, DOI: 10.1093/jnci/djad002.
  • Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate BiopsyLeapman M, Thiel C, Gordon I, Nolte A, Perecman A, Loeb S, Overcash M, Sherman J. Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate Biopsy European Urology 2023 PMID: 36635108, DOI: 10.1016/j.eururo.2022.12.008.
  • Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutationsRajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman M, Gore J, Paradysz A, Tilki D, Merseburger A, Morgan T, Briganti A, Palapattu G, Shariat S. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations Nature Reviews Urology 2023, 1-11. PMID: 36600087, DOI: 10.1038/s41585-022-00680-4.
  • Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladderRahman S, Lokeshwar S, Syed J, Javier-Desloges J, Press B, Choksi A, Rajwa P, Pradere B, Ploussard G, Kim J, Monaghan T, Renzulli J, Shariat S, Leapman M. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder Urologic Oncology Seminars And Original Investigations 2022 PMID: 36481253, DOI: 10.1016/j.urolonc.2022.09.008.
  • End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy.Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. JCO Oncology Practice 2022, op2200401. PMID: 36413741, DOI: 10.1200/op.22.00401.
  • Incidence of circumcision among insured adults in the United StatesNabavizadeh B, Li KD, Hakam N, Shaw NM, Leapman MS, Breyer BN. Incidence of circumcision among insured adults in the United States PLOS ONE 2022, 17: e0275207. PMID: 36251658, PMCID: PMC9576047, DOI: 10.1371/journal.pone.0275207.
  • Acceptance of Simulated Adult Patients With Medicaid Insurance Seeking Care in a Cancer Hospital for a New Cancer DiagnosisMarks VA, Hsiang WR, Nie J, Demkowicz P, Umer W, Haleem A, Galal B, Pak I, Kim D, Salazar MC, Berger ER, Boffa DJ, Leapman MS. Acceptance of Simulated Adult Patients With Medicaid Insurance Seeking Care in a Cancer Hospital for a New Cancer Diagnosis JAMA Network Open 2022, 5: e2222214. PMID: 35838668, PMCID: PMC9287756, DOI: 10.1001/jamanetworkopen.2022.22214.
  • PD41-04 DISTRIBUTION OF NATIONAL COMPREHENSIVE CANCER NETWORK RISK CLASSIFICATIONS USING MAGNETIC RESONANCE IMAGING-ULTRASOUND FUSION VERSUS SYSTEMIC 12 CORE BIOPSIESKhajir G, Press B, Sprenkle P, Washington S, Cooperberg M, Leapman M. PD41-04 DISTRIBUTION OF NATIONAL COMPREHENSIVE CANCER NETWORK RISK CLASSIFICATIONS USING MAGNETIC RESONANCE IMAGING-ULTRASOUND FUSION VERSUS SYSTEMIC 12 CORE BIOPSIES Investigative Urology 2022, 207: e690. DOI: 10.1097/ju.0000000000002602.04.
  • MP45-09 DISCRIMINATIVE SIGNIFICANCE OF PROSTATE BIOPSY DECIPHER SCORE TO PREDICT ADVERSE PATHOLOGY AND PATHOLOGICAL DISCORDANCE AT RADICAL PROSTATECTOMYKhajir G, Kumar D, Rahman S, Leapman M, Levi A, Humphrey P, Sprenkle P. MP45-09 DISCRIMINATIVE SIGNIFICANCE OF PROSTATE BIOPSY DECIPHER SCORE TO PREDICT ADVERSE PATHOLOGY AND PATHOLOGICAL DISCORDANCE AT RADICAL PROSTATECTOMY Investigative Urology 2022, 207: e765. DOI: 10.1097/ju.0000000000002611.09.
  • MP30-14 ENVIRONMENTAL IMPACT OF TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSYLeapman M, Thiel C, Gordon I, Nolte A, Perecman A, Overcash M, Sherman J. MP30-14 ENVIRONMENTAL IMPACT OF TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY Investigative Urology 2022, 207: e483. DOI: 10.1097/ju.0000000000002573.14.
  • MP40-14 OVERALL SURVIVAL AMONG ELDERLY PATIENTS WITH LOCALIZED UPPER TRACT UROTHELIAL CARCINOMA RECEIVING OBSERVATION VERSUS DEFINITIVE TREATMENTRahman S, Syed J, Lokeshwar S, Press B, Monaghan T, Leapman M. MP40-14 OVERALL SURVIVAL AMONG ELDERLY PATIENTS WITH LOCALIZED UPPER TRACT UROTHELIAL CARCINOMA RECEIVING OBSERVATION VERSUS DEFINITIVE TREATMENT Investigative Urology 2022, 207: e680. DOI: 10.1097/ju.0000000000002600.14.
  • MP53-11 FOUR KALLIKREIN PANEL TESTING AMONG MEDICARE BENEFICIARIES UNDERGOING PROSTATE CANCER SCREENINGLeapman M, Long J, Wang R, Sprenkle P, Ma X, Gross C. MP53-11 FOUR KALLIKREIN PANEL TESTING AMONG MEDICARE BENEFICIARIES UNDERGOING PROSTATE CANCER SCREENING Investigative Urology 2022, 207: e899. DOI: 10.1097/ju.0000000000002628.11.
  • Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies.Khajir G, Press B, Levi A, Sprenkle P, Leapman M. Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies. Journal Of Clinical Oncology 2022, 40: 283-283. DOI: 10.1200/jco.2022.40.6_suppl.283.
  • Factors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma.Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. Factors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2022, 40: 300-300. DOI: 10.1200/jco.2022.40.6_suppl.300.
  • Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate CancerBuck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer Urology Practice 2021, 9: 141-149. DOI: 10.1097/upj.0000000000000290.
  • Characteristics of Online Crowdfunding Campaigns for Urological Cancers in the United StatesHoller J, Hakam N, Nabavizadeh B, Sadighian M, Shibley W, Li K, Weiser L, Rios N, Enriquez A, Leapman M, Amend G, Breyer B. Characteristics of Online Crowdfunding Campaigns for Urological Cancers in the United States Urology Practice 2021, 9: 56-63. DOI: 10.1097/upj.0000000000000275.
  • Urology Practice Acquisitions by Private Equity Firms from 2011–2021Nie J, Demkowicz P, Hsiang W, Umer W, Chen E, McMahon G, Kenney P, Breyer B, Parikh R, Leapman M. Urology Practice Acquisitions by Private Equity Firms from 2011–2021 Urology Practice 2021, 9: 17-24. DOI: 10.1097/upj.0000000000000269.
  • Reply by AuthorsNie J, Demkowicz P, Hsiang W, Umer W, Chen E, McMahon G, Kenney P, Breyer B, Parikh R, Leapman M. Reply by Authors Urology Practice 2021, 9: 24-24. DOI: 10.1097/upj.0000000000000269.02.
  • Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents.Spees L, Dinan M, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Wheeler S. Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents. Journal Of Clinical Oncology 2021, 39: 116-116. DOI: 10.1200/jco.2020.39.28_suppl.116.
  • Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.Spees L, Wheeler S, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M. Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2021, 39: 87-87. DOI: 10.1200/jco.2020.39.28_suppl.87.
  • MP20-08 UROLOGY RESIDENCY TRAINING IN MEDICALLY UNDERSERVED AREAS THROUGH THE INTEGRATION OF A FEDERALLY QUALIFIED HEALTH CENTER ROTATIONJavier-Desloges J, Segal D, Khan A, Abello A, Motamedinia P, Hittelman A, Rosoff J, Stroup R, Leapman M. MP20-08 UROLOGY RESIDENCY TRAINING IN MEDICALLY UNDERSERVED AREAS THROUGH THE INTEGRATION OF A FEDERALLY QUALIFIED HEALTH CENTER ROTATION Investigative Urology 2021, 206 DOI: 10.1097/ju.0000000000002005.08.
  • PD38-10 AN INITIATIVE TO REDUCE DOOR TO INCISION TIME FOR PATIENTS WITH TESTICULAR TORSIONNguyen J, Buck M, Abello A, Casilla - Lennon M, Leapman M, Hittelman A, Teitelbaum J, Emerson B, Cavallo J, Kenney P, Lambert S. PD38-10 AN INITIATIVE TO REDUCE DOOR TO INCISION TIME FOR PATIENTS WITH TESTICULAR TORSION Investigative Urology 2021, 206 DOI: 10.1097/ju.0000000000002048.10.
  • MP26-14 RISK STRATIFICATION BY PROSTATE HEALTH INDEX PRIOR TO MRI-ULTRASOUND FUSION TARGETED BIOPSYKhajir G, Olawoyin O, Leapman M, Sprenkle P. MP26-14 RISK STRATIFICATION BY PROSTATE HEALTH INDEX PRIOR TO MRI-ULTRASOUND FUSION TARGETED BIOPSY Investigative Urology 2021, 206 DOI: 10.1097/ju.0000000000002023.14.
  • HF01-14 ANALYSIS OF ETIOLOGIC THEORIES PROPOSED TO EXPLAIN RACIAL DISPARITY IN PROSTATE CANCER OUTCOMES: A SCOPING REVIEWSegal D, Drew I, Buck M, Grimshaw A, Cavallo J, Leapman M. HF01-14 ANALYSIS OF ETIOLOGIC THEORIES PROPOSED TO EXPLAIN RACIAL DISPARITY IN PROSTATE CANCER OUTCOMES: A SCOPING REVIEW Investigative Urology 2021, 206 DOI: 10.1097/ju.0000000000001992.14.
  • HF02-11 DR. CLYDE LEROY DEMING: VISIONARY DURING A TURBULENT TIMELokeshwar S, Syed J, Amin J, Merenda C, Leapman M, Weiss R. HF02-11 DR. CLYDE LEROY DEMING: VISIONARY DURING A TURBULENT TIME Investigative Urology 2021, 206 DOI: 10.1097/ju.0000000000001993.11.
  • MP17-03 FACILITY-LEVEL FACTORS ASSOCIATED WITH DECREASING SHARE OF UROLOGIC CANCER PATIENTS WITH MEDICAID FOLLOWING IMPLEMENTATION OF THE AFFORDABLE CARE ACTDemkowicz P, Buck M, Nie J, Marks V, Leapman M. MP17-03 FACILITY-LEVEL FACTORS ASSOCIATED WITH DECREASING SHARE OF UROLOGIC CANCER PATIENTS WITH MEDICAID FOLLOWING IMPLEMENTATION OF THE AFFORDABLE CARE ACT Investigative Urology 2021, 206 DOI: 10.1097/ju.0000000000002002.03.
  • MP67-24 ASSESSING ONLINE CROWDFUNDING FOR UROLOGIC CANCER CARE USING AUTOMATED DATA EXTRACTIONRajwa P, Hopen P, Wojnarowicz J, Kaletka J, Paszkiewicz I, Lach-Wojnarowicz O, Paradysz A, Pradere B, Shariat S, Leapman M. MP67-24 ASSESSING ONLINE CROWDFUNDING FOR UROLOGIC CANCER CARE USING AUTOMATED DATA EXTRACTION Investigative Urology 2021, 206 DOI: 10.1097/ju.0000000000002028.24.
  • PD38-07 ANTIBIOTIC PROPHYLAXIS PRIOR TO OUTPATIENT UROLOGIC PROCEDURES: OUTCOMES FROM A DEPARTMENT-WIDE QUALITY IMPROVEMENT PROJECTBuck M, Nguyen J, Abello A, Leapman M, Cavallo J, Kenney P. PD38-07 ANTIBIOTIC PROPHYLAXIS PRIOR TO OUTPATIENT UROLOGIC PROCEDURES: OUTCOMES FROM A DEPARTMENT-WIDE QUALITY IMPROVEMENT PROJECT Investigative Urology 2021, 206 DOI: 10.1097/ju.0000000000002048.07.
  • MP40-10 TESTICULAR TUMOR SIZE IS ASSOCIATED WITH NONLOCALIZED DISEASE AT DIAGNOSISSharma V, Lec P, Fero K, Lenis A, Shirk J, Venkataramana A, Leapman M, Chamie K, Saigal C, Litwin M. MP40-10 TESTICULAR TUMOR SIZE IS ASSOCIATED WITH NONLOCALIZED DISEASE AT DIAGNOSIS Investigative Urology 2021, 206 DOI: 10.1097/ju.0000000000002055.10.
  • MP40-13 WHEN IS A SEMINOMA NOT A SEMINOMA? THE INCIDENCE, RISK FACTORS AND MANAGEMENT OF PATIENTS WITH TESTICULAR SEMINOMA WITH DISCORDANT ELEVATED SERUM ALPHA-FETOPROTEINFero K, Lec P, Sharma V, Lenis A, Low J, Litwin M, Leapman M, Chamie K. MP40-13 WHEN IS A SEMINOMA NOT A SEMINOMA? THE INCIDENCE, RISK FACTORS AND MANAGEMENT OF PATIENTS WITH TESTICULAR SEMINOMA WITH DISCORDANT ELEVATED SERUM ALPHA-FETOPROTEIN Investigative Urology 2021, 206 DOI: 10.1097/ju.0000000000002055.13.
  • PD46-08 MEDIATORS OF RACIAL DISPARITY IN THE USE OF PROSTATE MRILeapman M, Dinan M, Pasha S, Washington S, Ma X, Gross C. PD46-08 MEDIATORS OF RACIAL DISPARITY IN THE USE OF PROSTATE MRI Investigative Urology 2021, 206 DOI: 10.1097/ju.0000000000002060.08.
  • P0977 Assessing online crowdfunding for urologic cancer care using automated data extractionRajwa P, Hopen P, Wojnarowicz J, Kaletka J, Paszkiewicz I, Lach-Wojnarowicz O, Paradysz A, Pradere B, Shariat S, Leapman M. P0977 Assessing online crowdfunding for urologic cancer care using automated data extraction European Urology 2021, 79: s1377. DOI: 10.1016/s0302-2838(21)01350-6.
  • Change in facility-level share of Medicaid patients with cancer following implementation of the affordable care act.Buck M, Demkowicz P, Nie J, Marks V, Salazar M, Kenney P, Boffa D, Leapman M. Change in facility-level share of Medicaid patients with cancer following implementation of the affordable care act. Journal Of Clinical Oncology 2021, 39: e18543-e18543. DOI: 10.1200/jco.2021.39.15_suppl.e18543.
  • Accessibility of Telehealth services for cancer care at cancer hospital in the United States.Marks V, Hsiang W, Nie J, Umer W, Haleem A, Galal B, Pak I, Kim D, Kenney P, Leapman M. Accessibility of Telehealth services for cancer care at cancer hospital in the United States. Journal Of Clinical Oncology 2021, 39: 6535-6535. DOI: 10.1200/jco.2021.39.15_suppl.6535.
  • Access to cancer care for Medicaid patients at cancer hospitals in the United States.Marks V, Hsiang W, Nie J, Buck M, Demkowicz P, Umer W, Haleem A, Galal B, Pak I, Kim D, Kenney P, Leapman M. Access to cancer care for Medicaid patients at cancer hospitals in the United States. Journal Of Clinical Oncology 2021, 39: 6548-6548. DOI: 10.1200/jco.2021.39.15_suppl.6548.
  • Mediators of racial disparity in the use of prostate MRI.Leapman M, Dinan M, Pasha S, Washington S, Ma X, Gross C. Mediators of racial disparity in the use of prostate MRI. Journal Of Clinical Oncology 2021, 39: 6554-6554. DOI: 10.1200/jco.2021.39.15_suppl.6554.
  • Quantifying Treatment Selection Bias Effects on Survival in National Database Studies: Findings from Low-Risk Prostate Cancer PatientsMiccio J, Talcott W, Jairam V, Park H, Yu J, Leapman M, King M, Nguyen P, Kann B. Quantifying Treatment Selection Bias Effects on Survival in National Database Studies: Findings from Low-Risk Prostate Cancer Patients International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e397. DOI: 10.1016/j.ijrobp.2020.07.2439.
  • PT414 Similar survival outcomes among chemoradiation and neoadjuvant chemotherapy with radical cystectomy for small cell bladder cancerAbello A, Renzulli J, Park H, Leapman M, Kenney P. PT414 Similar survival outcomes among chemoradiation and neoadjuvant chemotherapy with radical cystectomy for small cell bladder cancer European Urology Open Science 2020, 19: e2283. DOI: 10.1016/s2666-1683(20)34148-3.
  • PT417 National variation in lymph node dissection and pathological yield at the time of radical cystectomyAbello A, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. PT417 National variation in lymph node dissection and pathological yield at the time of radical cystectomy European Urology Open Science 2020, 19: e2286. DOI: 10.1016/s2666-1683(20)34151-3.
  • Predicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity.Janet T, Danciu I, Justice A, Leapman M, McMahon B, Wadia R. Predicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity. Journal Of Clinical Oncology 2020, 38: e17609-e17609. DOI: 10.1200/jco.2020.38.15_suppl.e17609.
  • MP12-17 ASSOCIATION OF INSURANCE STATUS AND ACCESS TO UROLOGICAL CARE AT URGENT CARE CENTERSHsiang* W, Yousman L, Leapman M. MP12-17 ASSOCIATION OF INSURANCE STATUS AND ACCESS TO UROLOGICAL CARE AT URGENT CARE CENTERS Investigative Urology 2020, 203: e151. DOI: 10.1097/ju.0000000000000832.017.
  • MP61-12 NATIONAL VARIATION IN LYMPH NODE DISSECTION AND PATHOLOGICAL YIELD AT THE TIME OF RADICAL CYSTECTOMYAbello* A, Nawaf C, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. MP61-12 NATIONAL VARIATION IN LYMPH NODE DISSECTION AND PATHOLOGICAL YIELD AT THE TIME OF RADICAL CYSTECTOMY Investigative Urology 2020, 203: e939-e940. DOI: 10.1097/ju.0000000000000936.012.
  • MP68-05 CLINICAL OUTCOMES OF LOW-STAGE SARCOMATOID RENAL CELL CARCINOMAAbello* A, Nawaf C, Leapman M, Kenney P. MP68-05 CLINICAL OUTCOMES OF LOW-STAGE SARCOMATOID RENAL CELL CARCINOMA Investigative Urology 2020, 203: e1036. DOI: 10.1097/ju.0000000000000948.05.
  • PD55-02 SIMILAR SURVIVAL OUTCOMES AMONG CHEMORADIATION AND NEOADJUVANT CHEMOTHERAPY WITH RADICAL CYSTECTOMY FOR SMALL CELL BLADDER CANCERAbello* A, Nawaf C, Renzulli J, Park H, Leapman M, Kenney P. PD55-02 SIMILAR SURVIVAL OUTCOMES AMONG CHEMORADIATION AND NEOADJUVANT CHEMOTHERAPY WITH RADICAL CYSTECTOMY FOR SMALL CELL BLADDER CANCER Investigative Urology 2020, 203 DOI: 10.1097/ju.0000000000000965.02.
  • Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era.Miccio J, Ma S, Oladeru O, Yang D, Peters G, Jethwa K, Park H, Hurwitz M, Leapman M, Sprenkle P, Nguyen P, Yu J, Johung K. Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era. Journal Of Clinical Oncology 2020, 38: 748-748. DOI: 10.1200/jco.2020.38.6_suppl.748.
  • Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer.Leapman M, Presley C, Zhu W, Soulos P, Adelson K, Boffa D, Gross C. Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2019, 37: 9059-9059. DOI: 10.1200/jco.2019.37.15_suppl.9059.
  • P28 Rectal Radiation Dose Comparison Between Definitive Radiotherapy with Hydrogel Spacer Injection versus Post-prostatectomy Radiotherapy for Prostate CancerYang D, Yu J, An Y, Sprenkle P, Leapman M, Park H. P28 Rectal Radiation Dose Comparison Between Definitive Radiotherapy with Hydrogel Spacer Injection versus Post-prostatectomy Radiotherapy for Prostate Cancer International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e33. DOI: 10.1016/s0360-3016(19)30478-x.
  • FR02-04 UROLOGIC HEALTH THROUGHOUT THE HISTORY OF THE WHITE HOUSEAmirkhiz* K, Goland-Van Ryn M, Motamedinia P, Leapman M, Sprenkle P, Weiss R. FR02-04 UROLOGIC HEALTH THROUGHOUT THE HISTORY OF THE WHITE HOUSE Investigative Urology 2019, 201 DOI: 10.1097/01.ju.0000555417.67392.ee.
  • PD17-02 CLINICAL RISK BASED ASSOCIATIONS OF LYMPH NODE DISSECTION AND DETECTION YIELD AMONG MEN TREATED WITH RADICAL PROSTATECTOMY FOR PROSTATE CANCERAbello* A, Sprenkle P, Kenney P, Leapman M. PD17-02 CLINICAL RISK BASED ASSOCIATIONS OF LYMPH NODE DISSECTION AND DETECTION YIELD AMONG MEN TREATED WITH RADICAL PROSTATECTOMY FOR PROSTATE CANCER Investigative Urology 2019, 201 DOI: 10.1097/01.ju.0000555562.32224.0f.
  • PD58-05 UROLOGIC MALIGNANCIES: A COMPARISON OF OUTCOMES AFTER INDEX SURGERY BETWEEN ACADEMIC AND COMMUNITY HOSPITALSSyed* J, Abello A, Javier-DesLoges J, Leapman M, Kenney P. PD58-05 UROLOGIC MALIGNANCIES: A COMPARISON OF OUTCOMES AFTER INDEX SURGERY BETWEEN ACADEMIC AND COMMUNITY HOSPITALS Investigative Urology 2019, 201 DOI: 10.1097/01.ju.0000557173.74355.7e.
  • PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDERJavier-DesLoges* J, Abello A, Syed J, Sprenkle P, Hurwitz M, Kenney P, Leapman M. PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDER Investigative Urology 2019, 201 DOI: 10.1097/01.ju.0000557466.16539.88.
  • MP29-16 THE ASSOCIATION BETWEEN THE AFFORDABLE CARE ACT, INSURANCE STATUS, AND TREATMENT AMONG PATIENTS WITH TESTICULAR CANCERHsiang W, Jemal A, Nguyen K, Shuch B, Park H, Yu J, Gross C, Davidoff A, Leapman* M. MP29-16 THE ASSOCIATION BETWEEN THE AFFORDABLE CARE ACT, INSURANCE STATUS, AND TREATMENT AMONG PATIENTS WITH TESTICULAR CANCER Investigative Urology 2019, 201 DOI: 10.1097/01.ju.0000557551.36748.5c.
  • MP29-19 CHASING THE PACK: ASSOCIATION BETWEEN UROLOGY HOSPITAL RANKINGS AND SURGICAL OUTCOMEAbello* A, Syed J, Leapman M, Kenney P. MP29-19 CHASING THE PACK: ASSOCIATION BETWEEN UROLOGY HOSPITAL RANKINGS AND SURGICAL OUTCOME Investigative Urology 2019, 201 DOI: 10.1097/01.ju.0000557554.82490.aa.
  • Clinical risk-based associations of lymph node dissection and detection of metastasis among men treated with radical prostatectomy.Abello A, Kenney P, Leapman M. Clinical risk-based associations of lymph node dissection and detection of metastasis among men treated with radical prostatectomy. Journal Of Clinical Oncology 2019, 37: 284-284. DOI: 10.1200/jco.2019.37.7_suppl.284.
  • National trends and pathologic outcomes of neoadjuvant chemotherapy among patients with micropapillary variant urothelial carcinoma of the bladder.Javier-Desloges J, Abello A, Syed J, Leapman M. National trends and pathologic outcomes of neoadjuvant chemotherapy among patients with micropapillary variant urothelial carcinoma of the bladder. Journal Of Clinical Oncology 2019, 37: 477-477. DOI: 10.1200/jco.2019.37.7_suppl.477.
  • The nonsurgical management of upper tract urothelial carcinoma: A role for active surveillance?Syed J, Nguyen K, Javier-Desloges J, Leapman M, Raman J, Shuch B. The nonsurgical management of upper tract urothelial carcinoma: A role for active surveillance? Journal Of Clinical Oncology 2019, 37: 485-485. DOI: 10.1200/jco.2019.37.7_suppl.485.
  • Urologic malignancies: A comparison of outcomes after index surgery between academic and community hospitals.Syed J, Abello A, Javier-Desloges J, Leapman M, Kenney P. Urologic malignancies: A comparison of outcomes after index surgery between academic and community hospitals. Journal Of Clinical Oncology 2019, 37: 489-489. DOI: 10.1200/jco.2019.37.7_suppl.489.
  • Associations of rurality and disease outcomes in urologic malignancies.Abello A, Casilla-Lennon M, Kenney P, Leapman M. Associations of rurality and disease outcomes in urologic malignancies. Journal Of Clinical Oncology 2019, 37: 661-661. DOI: 10.1200/jco.2019.37.7_suppl.661.
  • 2119. Reducing Catheter-Associated Urinary Tract Infections Using an Evidence-Based Urine Culture Algorithm at an Academic Medical CenterAdvani S, Smith C, Fisher A, Sullivan L, Hittelman A, Leapman M, Juthani-Mehta M, Martinello R. 2119. Reducing Catheter-Associated Urinary Tract Infections Using an Evidence-Based Urine Culture Algorithm at an Academic Medical Center Open Forum Infectious Diseases 2018, 5: s622-s623. PMCID: PMC6252850, DOI: 10.1093/ofid/ofy210.1775.
  • Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate CancerLeapman MS, Wang R, Park HS, Yu JB, Weinreb JC, Gross CP, Ma X. Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer Urology 2018, 124: 98-106. PMID: 30107188, DOI: 10.1016/j.urology.2018.07.041.
  • MP44-16 VARIATION IN NATIONAL OPIOID PRESCRIBING PATTERNS FOLLOWING SURGERY FOR KIDNEY STONESLeapman M, DeRycke E, Skanderson M, Becker W, Makarov D, Gross C, Driscoll M, Motamedinia P, Bathulapalli H, Mattocks K, Brandt C, Haskell S, Bastian L. MP44-16 VARIATION IN NATIONAL OPIOID PRESCRIBING PATTERNS FOLLOWING SURGERY FOR KIDNEY STONES Investigative Urology 2018, 199: e594. DOI: 10.1016/j.juro.2018.02.1435.
  • MP80-02 LEVERAGING STRUCTURED DATA IN AN ENTERPRISE-WIDE ELECTRONIC HEALTH RECORD TO IDENTIFY RISK FACTORS FOR POSTOPERATIVE URINARY RETENTIONJavier-DesLoges J, Amirkhiz K, Su J, Kenney P, Advani S, Hittelman A, Leapman M. MP80-02 LEVERAGING STRUCTURED DATA IN AN ENTERPRISE-WIDE ELECTRONIC HEALTH RECORD TO IDENTIFY RISK FACTORS FOR POSTOPERATIVE URINARY RETENTION Investigative Urology 2018, 199: e1089. DOI: 10.1016/j.juro.2018.02.2690.
  • PD56-12 COMPARISON OF A LOW-COST IMMUNOHISTOCHEMISTRY MARKER PANEL WITH A CELL-CYCLE PROGRESSION ASSAY FOR THE PREDICTION OF OUTCOME AFTER RADICAL PROSTATECTOMYLeapman M, Nguyen H, Cowan J, Xue L, Stohr B, Simko J, Cooperberg M, Carroll P. PD56-12 COMPARISON OF A LOW-COST IMMUNOHISTOCHEMISTRY MARKER PANEL WITH A CELL-CYCLE PROGRESSION ASSAY FOR THE PREDICTION OF OUTCOME AFTER RADICAL PROSTATECTOMY Investigative Urology 2018, 199: e1066. DOI: 10.1016/j.juro.2018.02.2644.
  • MP10-14 INCIDENCE, RISK FACTORS, AND OUTCOMES OF C. DIFFICILE INFECTION FOLLOWING RADICAL CYSTECTOMY: A NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM (NSQIP) STUDYNguyen K, Hsiang W, Syed J, Nolte A, Lu A, Suarez-Sarmiento A, Ghabili K, Shuch B, Leapman M. MP10-14 INCIDENCE, RISK FACTORS, AND OUTCOMES OF C. DIFFICILE INFECTION FOLLOWING RADICAL CYSTECTOMY: A NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM (NSQIP) STUDY Investigative Urology 2018, 199: e122. DOI: 10.1016/j.juro.2018.02.360.
  • MP51-09 EXAMINING POST-OPERATIVE OPIOID PRESCRIBING PATTERNS FOLLOWING UROLOGIC SURGERY USING AN ENTERPRISE-WIDE ELECTRONIC MEDICAL RECORDSu J, Javier-DesLoges J, Leapman M. MP51-09 EXAMINING POST-OPERATIVE OPIOID PRESCRIBING PATTERNS FOLLOWING UROLOGIC SURGERY USING AN ENTERPRISE-WIDE ELECTRONIC MEDICAL RECORD Investigative Urology 2018, 199: e688. DOI: 10.1016/j.juro.2018.02.1640.
  • PD51-06 DETERMINANTS OF ACTIVE SURVEILLANCE IN PATIENTS WITH SMALL RENAL MASSESNguyen K, Nolte A, Alimi O, Hsiang W, Syed J, Suarez-Sarmiento A, Lu A, Ghabili K, Shuch B, Leapman M. PD51-06 DETERMINANTS OF ACTIVE SURVEILLANCE IN PATIENTS WITH SMALL RENAL MASSES Investigative Urology 2018, 199: e977-e978. DOI: 10.1016/j.juro.2018.02.2346.
  • MP34-07 DISPARITIES IN THE DIAGNOSIS AND MANAGEMENT OF METASTATIC PROSTATE CANCER IN YOUNG MENLu A, Amirkhiz K, Nguyen K, Hsiang W, Leapman M. MP34-07 DISPARITIES IN THE DIAGNOSIS AND MANAGEMENT OF METASTATIC PROSTATE CANCER IN YOUNG MEN Investigative Urology 2018, 199: e440. DOI: 10.1016/j.juro.2018.02.1099.
  • PD42-01 NATIONAL TRENDS IN THE MANAGEMENT OF PATIENTS WITH POSITIVE SURGICAL MARGINS AT THE TIME OF RADICAL PROSTATECTOMYAmirkhiz K, Nguyen K, Hsiang W, Syed J, Suarez-Sarmiento A, Shuch B, Park H, Yu J, Leapman M. PD42-01 NATIONAL TRENDS IN THE MANAGEMENT OF PATIENTS WITH POSITIVE SURGICAL MARGINS AT THE TIME OF RADICAL PROSTATECTOMY Investigative Urology 2018, 199: e814. DOI: 10.1016/j.juro.2018.02.1954.
  • MP53-10 ASSOCIATION OF SYSTEMATIC BIOPSY VS. MAGNETIC RESONANCE IMAGING/ULTRASOUND FUSION TARGETED BIOPSY WITH PROSTATE CANCER UPSTAGING AT RADICAL PROSTATECTOMYAmirkhiz K, Suarez-Sarmiento A, Nguyen K, Hsiang W, Amalraj S, Syed J, Leapman M, Schulam P, Sprenkle P. MP53-10 ASSOCIATION OF SYSTEMATIC BIOPSY VS. MAGNETIC RESONANCE IMAGING/ULTRASOUND FUSION TARGETED BIOPSY WITH PROSTATE CANCER UPSTAGING AT RADICAL PROSTATECTOMY Investigative Urology 2018, 199: e707-e708. DOI: 10.1016/j.juro.2018.02.1681.
  • MP77-07 HOW MANY CORES ARE NEEDED TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER ON TARGETED MRI-ULTRASOUND FUSION BIOPSY?Lu A, Amirkhiz K, Nguyen K, Leapman M, Sprenkle P. MP77-07 HOW MANY CORES ARE NEEDED TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER ON TARGETED MRI-ULTRASOUND FUSION BIOPSY? Investigative Urology 2018, 199: e1029-e1030. DOI: 10.1016/j.juro.2018.02.2595.
  • MP53-08 USE OF PROSTATE MAGNETIC RESONANCE IMAGING AMONG MEDICARE BENEFICIARIES WITH LOW-RISK PROSTATE CANCER IS ASSOCIATED WITH A HIGHER LIKELIHOOD OF DEFINITIVE TREATMENTLeapman M, Wang R, Park H, Yu J, Gross C, Ma X. MP53-08 USE OF PROSTATE MAGNETIC RESONANCE IMAGING AMONG MEDICARE BENEFICIARIES WITH LOW-RISK PROSTATE CANCER IS ASSOCIATED WITH A HIGHER LIKELIHOOD OF DEFINITIVE TREATMENT Investigative Urology 2018, 199: e707. DOI: 10.1016/j.juro.2018.02.1679.
  • MP17-12 UTILITY OF SERIAL MRI/ULTRASOUND FUSION TARGETED BIOPSY IN MEN WITH LOW RISK PROSTATE CANCER MANAGED WITH ACTIVE SURVEILLANCEHsiang W, Ghabili K, Lu A, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, Sprenkle P. MP17-12 UTILITY OF SERIAL MRI/ULTRASOUND FUSION TARGETED BIOPSY IN MEN WITH LOW RISK PROSTATE CANCER MANAGED WITH ACTIVE SURVEILLANCE Investigative Urology 2018, 199: e209. DOI: 10.1016/j.juro.2018.02.567.
  • PD38-10 IMPACT OF LYMPH NODE COUNT AND ADJUVANT THERAPY ON ONCOLOGIC OUTCOMES IN NODE POSITIVE PATIENTS WITH PROSTATE CANCERMasic S, Nguyen H, Cowan J, Leapman M, Carroll P. PD38-10 IMPACT OF LYMPH NODE COUNT AND ADJUVANT THERAPY ON ONCOLOGIC OUTCOMES IN NODE POSITIVE PATIENTS WITH PROSTATE CANCER Investigative Urology 2018, 199: e740. DOI: 10.1016/j.juro.2018.02.1757.
  • National trends in the management of patients with positive surgical margins at the time of radical prostatectomy.Ghabili K, Nguyen K, Hsiang W, Syed J, Suarez-Sarmiento A, Shuch B, Park H, Yu J, Leapman M. National trends in the management of patients with positive surgical margins at the time of radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 111-111. DOI: 10.1200/jco.2018.36.6_suppl.111.
  • Outcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance.Hsiang W, Ghabili K, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, Sprenkle P. Outcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2018, 36: 114-114. DOI: 10.1200/jco.2018.36.6_suppl.114.
  • Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy.Leapman M, Nguyen H, Cowan J, Xue L, Stohr B, Simko J, Cooperberg M, Carroll P. Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 118-118. DOI: 10.1200/jco.2018.36.6_suppl.118.
  • How many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy?Lu A, Ghabili K, Nguyen K, Leapman M, Sprenkle P. How many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy? Journal Of Clinical Oncology 2018, 36: 134-134. DOI: 10.1200/jco.2018.36.6_suppl.134.
  • Heterogeneity in early oncologic outcomes among men with NCCN intermediate-risk prostate cancer treated with radical prostatectomy.Ghabili K, Nguyen K, Lu A, Hsiang W, Shuch B, Leapman M. Heterogeneity in early oncologic outcomes among men with NCCN intermediate-risk prostate cancer treated with radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 144-144. DOI: 10.1200/jco.2018.36.6_suppl.144.
  • Is PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI?Ghabili K, Ghabili K, Swallow M, Swallow M, Suarez-Sarmiento A, Suarez-Sarmiento A, Syed J, Leapman M, Weinreb J, Sprenkle P. Is PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI? Journal Of Clinical Oncology 2018, 36: 149-149. DOI: 10.1200/jco.2018.36.6_suppl.149.
  • National determinants of active surveillance among patients with clinical stage 1A kidney tumors.Lu A, Nguyen K, Nolte A, Alimi O, Hsiang W, Ghabili K, Syed J, Shuch B, Leapman M. National determinants of active surveillance among patients with clinical stage 1A kidney tumors. Journal Of Clinical Oncology 2018, 36: 694-694. DOI: 10.1200/jco.2018.36.6_suppl.694.
  • Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa)Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg MR, Carroll PR. Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa) PLOS ONE 2017, 12: e0185535. PMID: 29016610, PMCID: PMC5634556, DOI: 10.1371/journal.pone.0185535.
  • Risk Stratification of Newly Diagnosed Prostate Cancer with Genomic PlatformsLeapman M, Carroll P. Risk Stratification of Newly Diagnosed Prostate Cancer with Genomic Platforms Urology Practice 2017, 4: 322-328. DOI: 10.1016/j.urpr.2016.06.008.
  • MP69-07 HASHTAG PEER-REVIEW: DOES EARLY SOCIAL MEDIA SUCCESS CORRELATE WITH CONVENTIONAL METRICS OF PUBLICATION IMPACT?Nguyen K, Gross C, Cooperberg M, Katz M, Hittelman A, Syed J, Schulam P, Leapman M. MP69-07 HASHTAG PEER-REVIEW: DOES EARLY SOCIAL MEDIA SUCCESS CORRELATE WITH CONVENTIONAL METRICS OF PUBLICATION IMPACT? Investigative Urology 2017, 197: e928-e929. DOI: 10.1016/j.juro.2017.02.2303.
  • PD65-11 DOES PI-RADS V2 SCORES PREDICT ADVERSE SURGICAL PATHOLOGY AT RADICAL PROSTATECTOMY?Nguyen H, Westphalen A, Niloufar A, Leapman M, Cowan J, Simko J, Shinohara K, Carroll P. PD65-11 DOES PI-RADS V2 SCORES PREDICT ADVERSE SURGICAL PATHOLOGY AT RADICAL PROSTATECTOMY? Investigative Urology 2017, 197: e1270. DOI: 10.1016/j.juro.2017.02.2961.
  • MP10-13 IMPACT OF HISTOLOGIC SUBTYPE ON BLADDER CANCER OUTCOMEEapen R, Washington S, Sanford T, Leapman M, Meng M, Porten S. MP10-13 IMPACT OF HISTOLOGIC SUBTYPE ON BLADDER CANCER OUTCOME Investigative Urology 2017, 197: e113. DOI: 10.1016/j.juro.2017.02.341.
  • Active Surveillance in Younger Men With Prostate CancerLeapman MS, Cowan JE, Nguyen HG, Shinohara KK, Perez N, Cooperberg MR, Catalona WJ, Carroll PR. Active Surveillance in Younger Men With Prostate Cancer Journal Of Clinical Oncology 2017, 35: jco.2016.68.005. PMID: 28346806, PMCID: PMC5466007, DOI: 10.1200/jco.2016.68.0058.
  • Impact of histologic subtype on bladder cancer outcome.Washington S, Sanford T, Leapman M, Meng M, Porten S. Impact of histologic subtype on bladder cancer outcome. Journal Of Clinical Oncology 2017, 35: 391-391. DOI: 10.1200/jco.2017.35.6_suppl.391.
  • Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer OutcomesLeapman MS, Cowan JE, Simko J, Roberge G, Stohr BA, Carroll PR, Cooperberg MR. Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes European Urology 2016, 71: 750-759. PMID: 27940155, DOI: 10.1016/j.eururo.2016.11.032.
  • Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance CandidacyLeapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy Investigative Urology 2016, 196: 1408-1414. PMID: 27352635, PMCID: PMC5542578, DOI: 10.1016/j.juro.2016.06.086.
  • PD42-03 PATHOLOGIC AND BIOCHEMICAL OUTCOMES AMONG AFRICAN-AMERICAN AND CAUCASIAN MEN WITH LOW-RISK PROSTATE CANCER IN THE SEARCH DATABASE: IMPLICATIONS FOR ACTIVE SURVEILLANCE CANDIDACYLeapman M, Freedland S, Aaronson W, Kane C, Terris M, Walker K, Amling C, Carroll P, Cooperberg M. PD42-03 PATHOLOGIC AND BIOCHEMICAL OUTCOMES AMONG AFRICAN-AMERICAN AND CAUCASIAN MEN WITH LOW-RISK PROSTATE CANCER IN THE SEARCH DATABASE: IMPLICATIONS FOR ACTIVE SURVEILLANCE CANDIDACY Investigative Urology 2016, 195: e987-e988. DOI: 10.1016/j.juro.2016.02.1755.
  • PI-03 A RANDOMIZED STUDY OF INTRA-OPERATIVE AUTOLOGOUS RETROPUBIC URETHRAL SLING ON URINARY CONTROL AFTER ROBOT ASSISTED RADICAL PROSTATECTOMYNguyen H, Leapman M, Punnen S, Cowan J, Cary C, Welty C, Cooperberg M, Meng M, Greene K, Porten S, Garcia M, Carroll P. PI-03 A RANDOMIZED STUDY OF INTRA-OPERATIVE AUTOLOGOUS RETROPUBIC URETHRAL SLING ON URINARY CONTROL AFTER ROBOT ASSISTED RADICAL PROSTATECTOMY Investigative Urology 2016, 195: e409-e410. DOI: 10.1016/j.juro.2016.02.1208.
  • MP15-19 FUSION MRI-ULTRASOUND BIOPSY DURING PROSTATE CANCER ACTIVE SURVEILLANCELeapman M, Tran G, Nguyen H, Cowan J, Westphalen A, Shinohara K, Carroll P. MP15-19 FUSION MRI-ULTRASOUND BIOPSY DURING PROSTATE CANCER ACTIVE SURVEILLANCE Investigative Urology 2016, 195: e159. DOI: 10.1016/j.juro.2016.02.2543.
  • MP79-11 EXTERNAL VALIDATION OF A PROGNOSTIC GLEASON GRADE CLASSIFICATION SYSTEMLeapman M, Cowan J, Roberge G, Eltemamy M, Simko J, Carroll P, Cooperberg M. MP79-11 EXTERNAL VALIDATION OF A PROGNOSTIC GLEASON GRADE CLASSIFICATION SYSTEM Investigative Urology 2016, 195: e1038-e1039. DOI: 10.1016/j.juro.2016.02.2009.
  • PD03-01 YOUNGER AGE IS ASSOCIATED WITH DECREASED RISK OF BIOPSY PROGRESSION DURING ACTIVE SURVEILLANCE FOR LOW AND INTERMEDIATE RISK PROSTATE CANCERLeapman M, Nguyen H, Cowan J, Perez N, Shinohara K, Catalona W, Cooperberg M, Carroll P. PD03-01 YOUNGER AGE IS ASSOCIATED WITH DECREASED RISK OF BIOPSY PROGRESSION DURING ACTIVE SURVEILLANCE FOR LOW AND INTERMEDIATE RISK PROSTATE CANCER Investigative Urology 2016, 195: e56. DOI: 10.1016/j.juro.2016.02.2089.
  • MP79-10 PROTON MAGNETIC RESONANCE IMAGING SPECTROSCOPY IMPROVES PREDICTION OF HIGH GRADE PROSTATE CANCER WHEN INTEGRATED IN PI-RADS 2Leapman M, Wang Z, Behr S, Kurhanewicz J, Zagoria R, Carroll P, Guimarães C, Westphalen A. MP79-10 PROTON MAGNETIC RESONANCE IMAGING SPECTROSCOPY IMPROVES PREDICTION OF HIGH GRADE PROSTATE CANCER WHEN INTEGRATED IN PI-RADS 2 Investigative Urology 2016, 195: e1038. DOI: 10.1016/j.juro.2016.02.2008.
  • MP80-01 PHOSPHODIESTERASE TYPE 5 INHIBITOR USE IS NOT ASSOCIATED WITH BIOCHEMICAL RECURRENCE AFTER DEFINITIVE THERAPY FOR PROSTATE CANCERLeapman M, Nguyen H, Cowan J, Porten S, Meng M, Cooperberg M, Carroll P. MP80-01 PHOSPHODIESTERASE TYPE 5 INHIBITOR USE IS NOT ASSOCIATED WITH BIOCHEMICAL RECURRENCE AFTER DEFINITIVE THERAPY FOR PROSTATE CANCER Investigative Urology 2016, 195: e1043. DOI: 10.1016/j.juro.2016.02.2033.
  • MP15-07 SERIAL ANATOMIC PROSTATE ULTRASOUND IMAGING DURING PROSTATE CANCER ACTIVE SURVEILLANCEEltemamy M, Leapman M, Cowan J, Shinohara K, Westphalen A, Carroll P. MP15-07 SERIAL ANATOMIC PROSTATE ULTRASOUND IMAGING DURING PROSTATE CANCER ACTIVE SURVEILLANCE Investigative Urology 2016, 195: e154. DOI: 10.1016/j.juro.2016.02.2531.
  • Relationship of phosphodiesterase type 5 inhibitor to biochemical recurrence after definitive therapy for prostate cancer.Leapman M, Cowan J, Nguyen H, Porten S, Cooperberg M, Carroll P. Relationship of phosphodiesterase type 5 inhibitor to biochemical recurrence after definitive therapy for prostate cancer. Journal Of Clinical Oncology 2016, 34: 119-119. DOI: 10.1200/jco.2016.34.2_suppl.119.
  • External validation of a prognostic Gleason grade classification system.Leapman M, Cowan J, Roberge G, Eltemamy M, Simko J, Carroll P, Cooperberg M. External validation of a prognostic Gleason grade classification system. Journal Of Clinical Oncology 2016, 34: 123-123. DOI: 10.1200/jco.2016.34.2_suppl.123.
  • Change in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance.Leapman M, Cowan J, Nguyen H, Cooperberg M, Carroll P. Change in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2016, 34: 124-124. DOI: 10.1200/jco.2016.34.2_suppl.124.
  • Pathologic and biochemical outcomes among African American and Caucasian men with low-risk prostate cancer in the search database: Implications for active surveillance candidacy.Leapman M, Freedland S, Aaronson W, Kane C, Terris M, Amling C, Carroll P, Cooperberg M. Pathologic and biochemical outcomes among African American and Caucasian men with low-risk prostate cancer in the search database: Implications for active surveillance candidacy. Journal Of Clinical Oncology 2016, 34: 76-76. DOI: 10.1200/jco.2016.34.2_suppl.76.
  • TRUS Biopsy: Is There Still a Role?Leapman M, Shinohara K. TRUS Biopsy: Is There Still a Role? 2016, 53-67. DOI: 10.1007/978-3-319-21485-6_4.
  • Clinical Risk Prediction Tools for Prostate Cancer: TNM to CAPRA—Should Risk Be Redefined?Leapman M, Cooperberg M. Clinical Risk Prediction Tools for Prostate Cancer: TNM to CAPRA—Should Risk Be Redefined? 2016, 33-52. DOI: 10.1007/978-3-319-21485-6_3.
  • A Case-Based Illustration of Urinary Symptoms Following Radiation Therapy for Prostate CancerPolland A, Leapman M, Stone N. A Case-Based Illustration of Urinary Symptoms Following Radiation Therapy for Prostate Cancer 2015, 151-172. DOI: 10.1007/978-3-319-23817-3_11.
  • MP42-12 CANCER OF THE PROSTATE RISK ASSESSMENT SCORE FOLLOWING BIOPSY GLEASON UPGRADE DURING PROSTATE CANCER ACTIVE SURVEILLANCE IS ASSOCIATED WITH ADVERSE PATHOLOGY AT PROSTATECTOMYLeapman M, Ameli N, Chu C, Hussein A, Welty C, Cooperberg M, Carroll P. MP42-12 CANCER OF THE PROSTATE RISK ASSESSMENT SCORE FOLLOWING BIOPSY GLEASON UPGRADE DURING PROSTATE CANCER ACTIVE SURVEILLANCE IS ASSOCIATED WITH ADVERSE PATHOLOGY AT PROSTATECTOMY Investigative Urology 2015, 193: e513. DOI: 10.1016/j.juro.2015.02.1597.
  • MP87-04 TIMING OF SALVAGE ANDROGEN DEPRIVATION THERAPY FOLLOWING PROSTATE RADIOTHERAPY DOES NOT ADVERSELY AFFECT ALL-CAUSE OR PROSTATE CANCER SPECIFIC SURVIVALSagalovich D, Leapman M, Sfakianos J, Hall S, Stock R, Stone N. MP87-04 TIMING OF SALVAGE ANDROGEN DEPRIVATION THERAPY FOLLOWING PROSTATE RADIOTHERAPY DOES NOT ADVERSELY AFFECT ALL-CAUSE OR PROSTATE CANCER SPECIFIC SURVIVAL Investigative Urology 2015, 193: e1085. DOI: 10.1016/j.juro.2015.02.1949.
  • PD47-02 IMPROVED PRE-RADICAL PROSTATECTOMY RISK STRATIFICATION USING PSA DENSITYWelty C, Leapman M, Brajtbord J, Cowan J, Cooperberg M, Carroll P. PD47-02 IMPROVED PRE-RADICAL PROSTATECTOMY RISK STRATIFICATION USING PSA DENSITY Investigative Urology 2015, 193: e961-e962. DOI: 10.1016/j.juro.2015.02.2746.
  • MP86-10 CLINICAL PROSTATE CANCER RISK PREDICTION DERIVED FROM TARGETED BIOPSYLeapman M, Shinohara K, Ameli N, Meng M, Cooperberg M, Carroll P. MP86-10 CLINICAL PROSTATE CANCER RISK PREDICTION DERIVED FROM TARGETED BIOPSY Investigative Urology 2015, 193: e1079. DOI: 10.1016/j.juro.2015.02.1919.
  • MP24-10 DECLINING USE OF URINARY HERBAL AND VITAMIN SUPPLEMENTS AMONG U.S. MEN IN LONGITUDINAL NATIONAL PROSTATE CANCER SCREENING COHORTSLeapman M, Crawford D, Poage W, Stone N. MP24-10 DECLINING USE OF URINARY HERBAL AND VITAMIN SUPPLEMENTS AMONG U.S. MEN IN LONGITUDINAL NATIONAL PROSTATE CANCER SCREENING COHORTS Investigative Urology 2015, 193: e279. DOI: 10.1016/j.juro.2015.02.1152.
  • MP53-18 ASSOCIATION BETWEEN A 17-GENE GENOMIC PROSTATE SCORE AND MULTI-PARAMETRIC PROSTATE MRI IN MEN WITH LOW AND INTERMEDIATE RISK PROSTATE CANCER (PCA)Leapman M, Westphalen A, Ameli N, Lawrence J, Febbo P, Cooperberg M, Carroll P. MP53-18 ASSOCIATION BETWEEN A 17-GENE GENOMIC PROSTATE SCORE AND MULTI-PARAMETRIC PROSTATE MRI IN MEN WITH LOW AND INTERMEDIATE RISK PROSTATE CANCER (PCA) Investigative Urology 2015, 193: e642-e643. DOI: 10.1016/j.juro.2015.02.1712.
  • PD15-12 DESIGN AND EARLY CLINICAL EXPERIENCE WITH A TACTILE FEEDBACK DRIVEN PELVIC FLOOR MUSCLE TRAINING SMARTPHONE APPGarcia M, Leapman M, Brajtbord J, Carroll P. PD15-12 DESIGN AND EARLY CLINICAL EXPERIENCE WITH A TACTILE FEEDBACK DRIVEN PELVIC FLOOR MUSCLE TRAINING SMARTPHONE APP Investigative Urology 2015, 193: e329. DOI: 10.1016/j.juro.2015.02.1329.
  • Association of magnitude of cancer of the prostate risk assessment score change following biopsy gleason upgrade during prostate cancer active surveillance with adverse pathology at prostatectomy.Leapman M, Ameli N, Chu C, Welty C, Hussein A, Cooperberg M, Carroll P. Association of magnitude of cancer of the prostate risk assessment score change following biopsy gleason upgrade during prostate cancer active surveillance with adverse pathology at prostatectomy. Journal Of Clinical Oncology 2015, 33: 76-76. DOI: 10.1200/jco.2015.33.7_suppl.76.
  • Association between a 17-gene genomic prostate score and multiparametric prostate MRI in men with low- and intermediate-risk prostate cancer (PCa).Leapman M, Westphalen A, Ameli N, Lawrence H, Febbo P, Cooperberg M, Carroll P. Association between a 17-gene genomic prostate score and multiparametric prostate MRI in men with low- and intermediate-risk prostate cancer (PCa). Journal Of Clinical Oncology 2015, 33: 83-83. DOI: 10.1200/jco.2015.33.7_suppl.83.
  • P045 The quality of nerve-sparing during radical prostatectomy affects sexual function and urinary continence recoveryCollingwood S, Kwon Y, Hobbs A, Katsigeorgis M, Mcbride R, Leapman M, Samadi D. P045 The quality of nerve-sparing during radical prostatectomy affects sexual function and urinary continence recovery European Urology Open Science 2014, 13: 125. DOI: 10.1016/s1569-9056(14)61268-9.
  • P046 The modulating effects of benign prostate hyperplasia medications on upgrading predictorsKwon Y, Mcbride R, Leapman M, Katsigeorgis M, Collingwood S, Hobbs A, Samadi D. P046 The modulating effects of benign prostate hyperplasia medications on upgrading predictors European Urology Open Science 2014, 13: 126. DOI: 10.1016/s1569-9056(14)61269-0.
  • V5-14 PERCUTANEOUS GAS-COOLED MICROWAVE ABLATION FOR SMALL RENAL MASSES: THE MOUNT SINAI EXPERIENCELeapman M, Jayadevan R, Phillips C, Hall S, Palese M, Fischman A. V5-14 PERCUTANEOUS GAS-COOLED MICROWAVE ABLATION FOR SMALL RENAL MASSES: THE MOUNT SINAI EXPERIENCE Investigative Urology 2014, 191: e620. DOI: 10.1016/j.juro.2014.02.1717.
  • FRII-05 FIVE DECADES OF UROLOGIC INVESTIGATION IN MICROGRAVITYLeapman M, Stock J. FRII-05 FIVE DECADES OF UROLOGIC INVESTIGATION IN MICROGRAVITY Investigative Urology 2014, 191: e628-e629. DOI: 10.1016/j.juro.2014.02.1743.
  • Urinary Retention and Incontinence after Low-Dose-Rate Brachytherapy for Prostate CancerLeapman M, Stone N. Urinary Retention and Incontinence after Low-Dose-Rate Brachytherapy for Prostate Cancer Current Bladder Dysfunction Reports 2013, 8: 236-241. DOI: 10.1007/s11884-013-0188-5.
  • 1203 PREDICTORS OF URINARY INCONTINENCE FOLLOWING PROSTATE BRACHYTHERAPYLeapman M, Stone N, Mock S, Hall S, Stock R. 1203 PREDICTORS OF URINARY INCONTINENCE FOLLOWING PROSTATE BRACHYTHERAPY Investigative Urology 2013, 189: e493. DOI: 10.1016/j.juro.2013.02.2557.
  • 1115 CIRCUMCISION REVERSAL: ANTIQUITY AND THE DEFICIENT PREPUCELeapman M, Stock J. 1115 CIRCUMCISION REVERSAL: ANTIQUITY AND THE DEFICIENT PREPUCE Investigative Urology 2013, 189: e456. DOI: 10.1016/j.juro.2013.02.707.
  • Hematuria After Prostate BrachytherapyLeapman M. Hematuria After Prostate Brachytherapy International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s410. DOI: 10.1016/j.ijrobp.2012.07.1086.

Clinical Trials

ConditionsStudy Title
ProstateA Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer
ProstateRandomized Three-Arm Trial to Evaluate the Effect of Neoadjuvant Apalutamide Alone or in Combination With Abiraterone Acetate and GnRH Agonist on Enhancing Surgical Outcome of Nerve-Sparing Radical Prostatectomy in Men With High-Risk Prostate Cancer
Other Male Genital; ProstateCustomized Ablation of the Prostate With the TULSA Procedure Against Radical Prostatectomy Treatment: a Randomized Controlled Trial for Localized Prostate Cancer (CAPTAIN)
ProstateSIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer
ProstateEvaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients With Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study
ProstateA Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Edit Profile